Enzalutamide
| Use attributes for filter ! | |
| Drug class | Nonsteroidal |
|---|---|
| Other names | MDV-3100; ASP-9785 |
| Metabolism | CYP2C8 |
| CYP3A4 | |
| Elimination half-life | Enzalutamide: 5. 8 days (range 2. 8–10. 2 days); NDME: 7. 8–8. 6 days |
| ATC code | L02BB04 (WHO) |
| Pronunciation | /ɛksˈtændi/ eks-TAN-dee |
| License data | EMA |
| DailyMed | |
| US | |
| FDA | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951670 |
About Enzalutamide
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.